EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of bimodal hepatitis B virus ribonuclease H and capsid assembly inhibitors

Daniel P Bradley, Caleb J Valkner, Qilan Li, Makafui Gasonoo, Marvin J Meyers, Georgia-Myrto Prifti, Dimitrios Moianos, Grigoris Zoidis, Adam Zlotnick, John E Tavis iD

PLOS Pathogens · 2025

DOI: 10.1371/journal.ppat.1012920 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von Daniel P Bradley und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, Missouri, United States of America. Hauptthemen laut MEDLINE: Hepatitis B virus, Ribonuclease H, Antiviral Agents, Virus Assembly. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis B virus (HBV) ribonuclease H (RNaseH) inhibitors are a potent class of antivirals that prevent degradation of the viral pregenomic RNA during reverse transcription and block formation of mature HBV DNAs. Development of HBV RNaseH inhibitors is entering advanced preclinical analyses. To ensure the mechanism of action was fully understood, we defined the effects of RNaseH inhibitors on other steps of HBV replication. Some N -hydroxypyridinedione (HPD) HBV RNaseH inhibitors significantly reduced accumulation of capsids in HBV-replicating cells. A representative HPD 1466 , with a 50% effective concentration against HBV replication of 0.25 µM, decreased capsid and core protein accumulation by 50–90% in HepDES19 and HepG2.2.15 cells. Surprisingly , 1466 did not affect pregenomic RNA encapsidation, demonstrating a specific effect on empty capsids. HBV genomic replication was not necessary for 1466 ’s inhibitory effect as it decreased capsid accumulation in cells transfected with replication-deficient mutants blocking pgRNA encapsidation (Δ-bulge), DNA synthesis (YMHA), and RNaseH (D702A) activities. 1466 also decreased capsid and core protein accumulation in cells transfected with a core protein expression plasmid, indicating that other HBV products are unneeded. 1466 reduced initial capsid assembly rates in biochemical assembly reactions employing purified core protein (Cp149), demonstrating a specific effect on HBV core protein. We conclude that the bimodal HPD HBV RNaseH inhibitor 1466 is the prototypic member of a new class of capsid assembly modulators (CAM) that inhibits capsid assembly rather than accelerating it, as all other CAM classes do. We propose that this class be called CAM-I, for CAM-inhibitor . These results lay the foundation for identifying bimodal HBV antivirals targeting the RNaseH and capsid assembly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B virusRibonuclease HAntiviral AgentsVirus AssemblyCapsidEnzyme InhibitorsHumansVirus ReplicationHep G2 CellsRNA, ViralCapsid Proteins

Substanzen

Ribonuclease HAntiviral AgentsEnzyme InhibitorsRNA, ViralCapsid Proteins

Autor:innen und Institutionen

  • Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, Missouri, United States of America.
  • Saint Louis University Institute for Drug and Biotherapeutic Innovation, Saint Louis, Missouri, United States of America.
  • Department of Molecular & Cellular Biology, Indiana University, Bloomington, Indiana, United States of America.
  • Department of Chemistry, Saint Louis University, Saint Louis, Missouri United States of America.
  • Department of Pharmacy, Division of Pharmaceutical Chemistry, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, Athens, Greece.

ORCID-Profile: John E Tavis

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
  • Gilead Sciences

Zitieren

APA

Bradley, D. P., Valkner, C. J., Li, Q., Gasonoo, M., Meyers, M. J., Prifti, G. M., Moianos, D., Zoidis, G., Zlotnick, A., & Tavis, J. E. (2025). Discovery of bimodal hepatitis B virus ribonuclease H and capsid assembly inhibitors. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012920

Vancouver

Bradley DP, Valkner CJ, Li Q, Gasonoo M, Meyers MJ, Prifti GM, et al. Discovery of bimodal hepatitis B virus ribonuclease H and capsid assembly inhibitors. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1012920

BibTeX
@article{Bradley2025,
  author = {Bradley, Daniel P and Valkner, Caleb J and Li, Qilan and Gasonoo, Makafui and Meyers, Marvin J and Prifti, Georgia-Myrto and Moianos, Dimitrios and Zoidis, Grigoris and Zlotnick, Adam and Tavis, John E},
  title = {Discovery of bimodal hepatitis B virus ribonuclease H and capsid assembly inhibitors},
  journal = {PLOS Pathogens},
  year = {2025},
  doi = {10.1371/journal.ppat.1012920}
}
Kostenlos starten →